Home   /   Taxonomy   /   Term

vaccine

Covid-19

Sinopharm says second-generation vaccine approved for trial

The improved vaccine has already been approved by the United Arab Emirates as a booster shot
Three doses of Pfizer-BioNTech vaccine may neutralise Omicorn - THE EDGE SINGAPORE

Covid-19

Three doses of Pfizer-BioNTech vaccine may neutralise Omicron

Initial laboratory studies demonstrate that three doses of the Pfizer-BioNTech Covid-19 Vaccine neutralize the Omicron variant
Moderna CEO sparks slump reiterating omicron may need new shots - THE EDGE SINGAPORE

Covid-19

Moderna CEO sparks slump reiterating omicron may need new shots

There is no way the current shots will provide the same level of protection against omicron as they do against delta.
Moderna says new vaccine for omicron may be ready in early 2022 - THE EDGE SINGAPORE

Covid-19

Moderna says new vaccine for Omicron may be ready in early 2022

"The remarkable thing about the mRNA vaccines, the Moderna platform, is that we can move very fast."

Covid-19

Clearing the path to vaccinating the world

The longer the pandemic goes on, the greater its costs and risks. This is about self-interest as much as benevolence.
Updated version of Covid-19 vaccine needed by middle of 2022 as new variants mutate, says BioNTech CEO - THE EDGE SINGAPORE

Covid-19

Updated version of Covid-19 vaccine needed by middle of 2022 as new variants mutate, says BioNTech CEO

"This virus will stay, and the virus will further adapt," says Sahin.

Covid-19

Wealthy nations will have 1.2 billion doses they don’t need

A more coordinated effort is needed to allow countries with ample supplies to resell and donate doses
PM Lee receives Covid-19 vaccine, calls the shot 'painless' and 'effective' - THE EDGE SINGAPORE

Covid-19

PM Lee receives Covid-19 vaccine, calls the shot 'painless' and 'effective'

Lee also urged Singaporeans to get the vaccine when it is made available to them, as it will “make us safer”.

Covid-19

Pfizer to send US 100 million more vaccine doses

Pfizer shares gained 1.5% to US$37.29 at 10:09 a.m. in New York on Wednesday.

Covid-19

AstraZeneca vaccine on hold as trial user contract mysterious illness

This is a routine action that took place after one person developed an unexplained illness.
×